Literature DB >> 9036953

Reciprocal regulation of CD30 expression on CD4+ T cells by IL-4 and IFN-gamma.

T Nakamura1, R K Lee, S Y Nam, B K Al-Ramadi, P A Koni, K Bottomly, E R Podack, R A Flavell.   

Abstract

Prior studies have implicated CD30 as a marker for Th2 cells, but the mechanism that underlies this correlation was unknown. We show here that CD30 was expressed on activated CD4+ T cells in the presence of IL-4. In the absence of endogenously produced IL-4, however, even Th2 lineage cells lost CD30 expression. Thus, CD30 is not an intrinsic marker of Th2 cells, but is inducible by IL-4. CD30 was also found to be down-regulated by IFN-gamma. Committed Th1 effector cells do not express CD30, although differentiating Th1 lineage cells temporarily express CD30. The transient expression of CD30 on differentiating Th1 lineage cells was mainly the result of endogenously produced IL-4 induced by IL-12. Culture of IL-12-primed cells under conditions that reverse the phenotype (Ag plus IL-4) resulted in two cell populations based upon their ability to express CD30. One population responded to IL-4 upon restimulation and became a CD30-positive, Th0-like cell population, while the other remained CD30 negative and synthesized only IFN-gamma. Thus, CD30 expressed on CD4+ T cells reflected the ability of CD4+ T cells to respond to IL-4.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9036953

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  Regulation of CD30 antigen expression and its potential significance for human disease.

Authors:  M E Kadin
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  Increased levels of soluble CD30 in plasma of patients with Plasmodium falciparum malaria.

Authors:  Kåre Kemp; Jørgen A L Kurtzhals; Bartholomew D Akanmori; Victoria Adabayeri; Bamenla Q Goka; Charlotte Behr; Lars Hviid
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

3.  Serum levels of soluble CD30 are increased in ulcerative colitis (UC) but not in Crohn's disease (CD).

Authors:  R Giacomelli; A Passacantando; I Parzanese; P Vernia; N Klidara; F Cucinelli; R Lattanzio; E Santori; P Cipriani; R Caprilli; G Tonietti
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

4.  Expression of CD30 mRNA, CD30L mRNA and a variant form of CD30 mRNA in restimulated peripheral blood mononuclear cells (PBMC) of patients with helminthic infections resembling a Th2 disease.

Authors:  J Kilwinski; T Berger; J Mpalaskas; S Reuter; W Flick; P Kern
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

5.  Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells.

Authors:  A Cerutti; A Schaffer; R G Goodwin; S Shah; H Zan; S Ely; P Casali
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

Review 6.  Deciphering CD30 ligand biology and its role in humoral immunity.

Authors:  Mary K Kennedy; Cynthia R Willis; Richard J Armitage
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

7.  Thiols decrease cytokine levels and down-regulate the expression of CD30 on human allergen-specific T helper (Th) 0 and Th2 cells.

Authors:  A Bengtsson ; M Lundberg; J Avila-Cariño; G Jacobsson; A Holmgren; A Scheynius
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

8.  Progressive polarization towards a T helper/cytotoxic type-1 cytokine pattern during age-dependent maturation of the immune response inversely correlates with CD30 cell expression and serum concentration.

Authors:  M Krampera; F Vinante; L Tavecchia; L Morosato; M Chilosi; S Romagnani; M E Zanolin; G Pizzolo
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

Review 9.  CD30: from basic research to cancer therapy.

Authors:  Hiromi Muta; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 10.  Modulating the Th1/Th2 balance in inflammatory arthritis.

Authors:  B Müller; U Gimsa; N A Mitchison; A Radbruch; J Sieper; Z Yin
Journal:  Springer Semin Immunopathol       Date:  1998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.